[go: up one dir, main page]

MXPA02004671A - Conjugados de interferon gamma. - Google Patents

Conjugados de interferon gamma.

Info

Publication number
MXPA02004671A
MXPA02004671A MXPA02004671A MXPA02004671A MXPA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A
Authority
MX
Mexico
Prior art keywords
polypeptide
interferon gamma
amino acid
conjugate
conjugates
Prior art date
Application number
MXPA02004671A
Other languages
English (en)
Inventor
Karsten Hansen Christian
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA02004671A publication Critical patent/MXPA02004671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se expone un conjugado que exhibe una actividad interferon gamma y comprende al menos una primera entidad no polipeptidica enlazada covalentemente con un polipeptido de IFG. El polipeptido comprende una secuencia de aminoacidos que difiere de aquella de un polipeptido de IFNG original en al menos un residuo de aminoacido introducido y/o al menos eliminado que comprende un grupo de union para la entidad sin polipeptido. El conjugado se puede utilizar para el tratamiento de diversas enfermedades.
MXPA02004671A 1999-11-12 2000-11-13 Conjugados de interferon gamma. MXPA02004671A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901631 1999-11-12
US16629399P 1999-11-18 1999-11-18
DKPA200000447 2000-03-17
PCT/DK2000/000631 WO2001036001A2 (en) 1999-11-12 2000-11-13 Interferon gamma conjugates

Publications (1)

Publication Number Publication Date
MXPA02004671A true MXPA02004671A (es) 2004-09-10

Family

ID=27221366

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004671A MXPA02004671A (es) 1999-11-12 2000-11-13 Conjugados de interferon gamma.

Country Status (17)

Country Link
US (3) US7232562B2 (es)
EP (1) EP1231943A1 (es)
JP (1) JP2003513681A (es)
KR (1) KR20020065517A (es)
BG (1) BG106790A (es)
BR (1) BR0015506A (es)
CA (1) CA2390292A1 (es)
CZ (1) CZ20021836A3 (es)
HR (1) HRP20020387A2 (es)
HU (1) HUP0203409A3 (es)
IL (2) IL149267A0 (es)
IS (1) IS6367A (es)
MX (1) MXPA02004671A (es)
NO (1) NO20022251L (es)
PL (1) PL356007A1 (es)
SK (1) SK8292002A3 (es)
WO (1) WO2001036001A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
IL149267A0 (en) 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US6964761B1 (en) 2001-12-12 2005-11-15 New York University Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DE60333758D1 (de) * 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004019758A2 (en) * 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2004099245A1 (de) * 2003-05-05 2004-11-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Stabilisiertes interferon-ϝ
EP1633317A4 (en) 2003-05-16 2008-08-20 Intermune Inc Synthetic chemokine receptor ligands and methods of use therefor
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
JP2007504169A (ja) * 2003-08-29 2007-03-01 ダイアックス コーポレーション 修飾されたプロテアーゼインヒビター
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP3269381B1 (en) 2005-11-23 2020-10-07 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
AU2008289005A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
KR20220156979A (ko) 2012-11-02 2022-11-28 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
CA2926161C (en) * 2013-10-04 2023-03-14 Engeneic Molecular Delivery Pty Ltd Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
CA2942713A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
TWI737583B (zh) 2014-11-06 2021-09-01 藥華醫藥股份有限公司 用於長效型干擾素之劑量方案
SMT202300166T1 (it) 2014-12-03 2023-07-20 Celgene Corp Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
WO2016191723A1 (en) * 2015-05-27 2016-12-01 Northwestern University Carbohydrate-modified particles and particulate formulations for modulating an immune response
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
US11084859B2 (en) * 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
JP2021531814A (ja) * 2018-07-30 2021-11-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターフェロン−ガンマバイアス型アゴニスト
CA3120153A1 (en) * 2018-11-20 2020-05-28 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA831094B (en) 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4835256A (en) * 1982-09-30 1989-05-30 New York University & Juridical Foundation Human gamma interferon polypeptide having glutamine as the ninth n-terminal amino acid
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
JPH0740925B2 (ja) 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPH0788398B2 (ja) 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4758656A (en) * 1983-12-26 1988-07-19 Kyowa Hakko Kogyo Co., Ltd. Novel human interferon-gamma polypeptide derivative
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
US4921698A (en) * 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3536939A1 (de) 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
GB8619725D0 (en) 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) * 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
US4944941A (en) * 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
DE3730331A1 (de) 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
BG52073B2 (en) 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
US5241072A (en) * 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
JPH06501001A (ja) 1990-08-31 1994-01-27 シェリング・コーポレーション ヒトインターフェロン−γ４−１３４，その機能的均等物およびこれらの物質の使用法および組成物
DE4036856C1 (es) 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH0770195A (ja) * 1993-08-23 1995-03-14 Yutaka Mizushima 糖修飾インターフェロン
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DE69430251T2 (de) * 1993-11-10 2002-11-07 Enzon, Inc. Verbesserte interferon-polymerkonjugate
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
DE19535853C2 (de) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0795332B1 (en) 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medical use of gamma-interferon in interstitial lung diseases
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
KR20020053064A (ko) 1999-09-28 2002-07-04 아마릴로 바이오싸이언시스, 인크 질병 치료를 위한 저용량의 ｉｆｎ-감마
IL149267A0 (en) 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates

Also Published As

Publication number Publication date
US7232562B2 (en) 2007-06-19
IL149267A0 (en) 2002-11-10
US20030153046A1 (en) 2003-08-14
HRP20020387A2 (en) 2005-10-31
JP2003513681A (ja) 2003-04-15
CA2390292A1 (en) 2001-05-25
BG106790A (bg) 2003-04-30
PL356007A1 (en) 2004-05-31
WO2001036001A3 (en) 2001-11-15
BR0015506A (pt) 2002-07-23
KR20020065517A (ko) 2002-08-13
HUP0203409A3 (en) 2005-06-28
HUP0203409A2 (hu) 2003-01-28
CZ20021836A3 (cs) 2002-08-14
WO2001036001A2 (en) 2001-05-25
EP1231943A1 (en) 2002-08-21
NO20022251L (no) 2002-07-05
SK8292002A3 (en) 2002-12-03
IS6367A (is) 2002-04-29
NO20022251D0 (no) 2002-05-10
IL149267A (en) 2008-07-08
US7504237B2 (en) 2009-03-17
US20080176323A1 (en) 2008-07-24
US20060194951A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
MXPA02004671A (es) Conjugados de interferon gamma.
YU32402A (sh) Konjugati gama interferona
WO2001051510A3 (en) G-csf conjugates
GR3034204T3 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
WO2001015736A3 (en) Interferon-beta conjugates
BG105709A (en) Piperidines as ccr5 modulatiors
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
DE69835201D1 (en) Neoglycoproteine
BE2013C064I2 (es)
AU2295895A (en) Dosage forms and method for ameliorating male erectile dysfunction
YU75701A (sh) Farmaceutski preparat
HUP0200297A2 (en) Method for acylating peptides and the glutaminic acid derivatives as acylating agents
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
IL138665A0 (en) Peptide factor
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
UA65561A (en) Therapeutic agent for lymphatic tumors
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
TR200200599T2 (tr) İnsan insülini monomerik analogları.
BG103196A (en) Crystalline pharmaceutical product
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive

Legal Events

Date Code Title Description
FG Grant or registration